Tenax Therapeutics, Inc. (NASDAQ: TENX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that the company will host its first Analyst Day event on Monday, April 13, 2015, from 9:00am – 12:00pm ET at Le Parker Meridien hotel in New York City.

Members of the Tenax management team and guest speakers will discuss the company’s lead clinical asset, levosimendan, with particular focus on the candidate’s full clinical experience and data, the ongoing Phase 3 LEVO-CTS trial for levosimendan in cardiac surgery, and the rationale for levosimendan in additional indications including the ongoing LeoPARDS trial for septic shock.

Speakers scheduled to present at the event include:

Piero Pollesello, PhD, Adj. Prof., FESC
Orion Pharma

Matti Kivikko, MD, PhD
Cardiologist, Medical Advisor to Orion Pharma

John Luber, MD, FACS
Franciscan Heart Center, Tacoma, Washington
LEVO – CTS Steering Committee

Wolfgang Toller, MD
University Hospital Graz, Austria
LEVO – CTS Steering Committee

Giovanni Landoni, MD
Vita-Salute University of Milan, Italy

Anthony Gordon, MD, FRCA, FFICM
11N, Imperial College/Charing Cross Hospital
Chief Investigator of LeoPARDS trial

Paula Bokesch, MD, FAAP
Chief Medical Officer, Tenax Therapeutics, Inc.

A live audio webcast of the event with presentation slides can be accessed under “Events and Presentations” in the Investors section of the Company’s website at www.tenaxthera.com, and an archived replay of the webcast will be available on the website following the event.

About Tenax Therapeutics

Tenax Therapeutics, Inc. (formerly Oxygen Biotherapeutics) is a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market. The company owns the North American rights to develop and commercialize levosimendan, and the United States Food and Drug Administration (FDA) has granted Fast Track status for levosimendan for the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome (LCOS). The company is currently enrolling a Phase 3 trial with levosimendan in that indication. For more information, visit www.tenaxthera.com.


Contacts

Investor Contact
Stern Investor Relations, Inc.
Jesse Baumgartner, 212-362-1200
jesse@sternir.com
or
Media Contact
Porter Novelli
Chad Hyett, 212-601-8242
chad.hyett@porternovelli.com